Plaque, Atherosclerotic

The supplied material supports endothelial activation/dysfunction as the initiating event in plaque formation. It also links plaque development to accumulation of lipids and lipoproteins in the arterial intima, together with inflammatory activation and contributions from vascular smooth muscle cells and macrophages.

Atherosclerotic plaque develops through a sequence that begins with endothelial activation, followed by leukocyte recruitment, lipid accumulation, fibrous element deposition, and calcification. Inflammation is described as orchestrating plaque initiation and progression, while smooth muscle cell phenotypic switching, proliferation, apoptosis, and senescence shape plaque composition and stability. Macrophages contribute to local inflammation, plaque growth, thrombosis, and the formation of lipid-rich necrotic cores.

The grounding explicitly identifies sex as an important risk factor. It also states that inflammatory mediators can link traditional and emerging risk factors with atherogenesis, but it does not specify those factors individually.

The supplied grounding supports drug therapy and diagnostic imaging as major management modalities, but it does not specify particular drug classes for routine treatment. It also indicates that macrophage-targeted imaging and nanoparticle-based approaches are being developed to identify advanced plaques and assess plaque-related pathology. Beyond these broad modalities, the grounding does not provide enough detail to define a standard treatment class.